Get to Know Verigraft: Natural personalized tissue therapies to cure severe and chronic diseases
Get to Know Verigraft: Natural personalized tissue therapies to cure severe and chronic diseases
VERIGRAFT, a Swedish biotechnology company, is leading the way in personalized tissue therapies for cardiovascular diseases. Traditional grafts often fail due to rejection, infections, or limited durability. VERIGRAFT addresses these challenges by engineering highly compatible, durable grafts that improve patient outcomes. Clinical trials are already demonstrating their safety and effectiveness.
This session is designed for doctors, researchers, investors, and healthcare enthusiasts, providing an in-depth look at VERIGRAFT's approach to personalized vascular therapies and its potential to revolutionize cardiovascular care.
Explore the details: https://capitalcell.com/en/campaign/verigraft/
What will we cover in these sessions?
What is Verigraft?
Discover the team behind Verigraft, their mission, current progress, and future plans.
Why is this project so relevant?
Dr. Jan Holgersson, M.D., Ph.D., is a recognized expert in transplantation immunology with a distinguished career in both clinical and academic fields. As Chairman and Co-founder of VERIGRAFT, Professor of Transplantation Immunology at the University of Gothenburg, and Head of the Department of Clinical Immunology and Transfusion Medicine, he also leads the Tissue Typing and Stem Cell Labs at Sahlgrenska University Hospital.
During the session, Dr. Holgersson will provide his perspective on the potential of VERIGRAFT’s personalized tissue therapies to address key challenges in cardiovascular care and improve patient outcomes.
Q&A Session
Get answers to your questions about Capital Cell, how it works, and how you can be part of this journey.
Spread the Word
Share this webinar with your network to help advance the future of tissue transplants. See you soon!